



Programme

Friday, 21 November 2014

09:30-10:00	Welcome coffee	
10:00-10:15 15'	Welcome	Chairs: George Coukos, CH and Rolf A. Stahel, CH
10:15-10:45 30'	Session 1 – Opening Keynote lecture Immunotherapy advances in haematological malignancies	Chairs: Rolf A. Stahel, CH and Robert Hawkins, UK
30'	Adoptive immunotherapy	James Yang, US
10:45-11:15	Coffee Break	
11:15-12:10 55'	Session 2 Haematological malignancies & myeloma	Chairs: Martin Pule, UK and TBC
20'	CD19 targeted T-cell therapy	Marcela Maus, US
20'	Targeting leukemia with TCR transduced t-cells	Aude Chapuis, US
15'	General Discussion / Q&A	
12:10-13:10	Lunch	
13:10-14:45 95'	Session 3 Cancer antigens – new horizons	Chairs: Ignacio Melero, ES and Alan Rickinson, UK
20'	Transduction of modified TCRs, model with MAGE-A1 specific TCRs	Reno Debets, NL
20'	Defining the role of mutated antigens	John Haanen, NL
20'	Alternative tumour antigens and the tumour proteome	Benoit van den Eynde, BE
20'	Novel cancer antigens for personalized immunotherapies	Harpreet Singh, DE
15'	General Discussion / Q&A	
14:45-15:15	Coffee break	
15:15-16:50 95'	Session 4 T-cell engineering	Chairs: George Coukos, CH and Dan Powell, US
20'	Clinical development of adoptive cell therapy	Robert Hawkins, UK
20'	Developing T cell receptors with improved affinity	Nathalie Rufer, CH
20'	CAR engineering with new costimulatory domains	Dan Powell, US
20'	Universal T-cells	Martin Pule, UK
15'	General Discussion / Q&A	

Friday, 21 November 2014, cont.

16:50-17:25 35'	Session 5 Panel Discussion - T-cells	Chair: George Coukos, CH
----------------------------	---	---------------------------------

17:25-18:45 80'	Session 6 Best Abstracts Session	Chair: John Haanen, NL and Olivier Michielin, CH
10'	1O - Role of PDL1 expression and tumor infiltrating lymphocytes (TILs) in glioblastoma (GBM) and brain metastases (BM)	Anna Berghoff, AT
10'	Invited Discussant, abstract 1O	Hideho Okada, US
10'	2O - Activation of T cells upon treatment with bispecific antibodies correlates with the expression of co-inhibitory receptors on tumor-infiltrating lymphocytes in human lung cancer	Daniela Thommen, CH
10'	Invited Discussant, abstract 2O	Dan Powell, US
10'	3O - Long-term maintenance therapy with the TLR-9 agonist MGN1703 in a subgroup of metastatic colorectal cancer patients from the IMPACT study	Werner Scheithauer, AT
10'	Invited Discussant, abstract 3O	TBC
10'	4O - Evaluating the place of interleukin-2 in the management of metastatic renal cell cancer (mRCC) in the era of targeted therapy	Manon Evans, UK
10'	Invited Discussant, abstract 4O	John Haanen, NL

18:45-19:15	Welcome reception and Poster viewing
--------------------	---

Saturday, 22 November 2014

08:30-09:45 75'	Session 7 Immune checkpoint blockade	Chairs: Solange Peters, CH and Lieping Chen, US
20'	Tumor site immune modulation	Lieping Chen, US
20'	PD-1 blockade	Charles Drake, US
20'	Combination of checkpoint blockade with vaccines	Jeffrey Weber, US
15'	General Discussion / Q&A	All

09:45-10:15	Coffee break
--------------------	---------------------

10:15-11:30 75'	Session 8 Immuno-Oncology clinical studies across tumour types I	Chairs: Ulrich Keilholz, DE and David McDermott, US (ACC)
20'	An overview of melanoma	Olivier Michielin, CH
20'	Prostate cancer	Charles Drake, US
20'	An overview of renal cancer	David McDermott, US
15'	General Discussion/ Q&A	All

11:30-12:45 75'	Session 9 Immuno-Oncology clinical studies across tumour types II	Chairs: Rolf A. Stahel, CH and David Carbone, US
20'	The immune system and lung cancer	David Carbone, US
20'	Immune checkpoint inhibitors in lung cancer	Solange Peters, CH
20'	Brain tumour immunotherapy	Hideho Okada, US
15'	General Discussion/ Q&A	

Saturday, 22 November 2014 , cont.

12:45 – 13:45	Lunch
---------------	-------

13:45-15:00 75'	Session 10 Immuno-Oncology clinical studies across tumour types III	Chairs: James Yang, US and Giuseppe Curigliano, IT
20'	Colon – what has been tried (retrospective review)	Dirk Arnold, DE
20'	Ovarian cancer	George Coukos, CH
20'	Breast cancer	Giuseppe Curigliano, IT
15'	General Discussion/ Q&A	

15:00-15:30	Coffee break
-------------	--------------

15:30-16:25 55'	Session 11 Viral associated diseases	Chairs: John Haanen, NL and Peter Stern, UK
20'	EBV vaccines	Alan Rickinson, UK
20'	HPV vaccines	Peter Stern, UK
15'	General Discussion/ Q&A	

16:25-16:55 30'	Session 12 - Closing Keynote lecture	Chairs: Rolf A. Stahel, CH and George Coukos, CH
30'	Clinical management of the immunotherapy patient	Jeffrey Weber, US

16:55-17:30 35'	Session 13 Panel Discussion - Antigens	Chairs: Ulrich Keilholz, DE and Harpreet Singh, DE
----------------------------------	---	---

17:30-17:45 15'	Closing remarks	Chairs: George Coukos, CH and Rolf A. Stahel, CH
----------------------------------	------------------------	---

Posters – Displayed throughout the Symposium

5P	Microtubule-depolymerizing agents used in antibody-drug-conjugates induce antitumor activity by stimulation of dendritic cells	Kea Martin, CH
6P	Investigation of the Helicase Antigen (HAGE) as immunotherapeutic target for breast cancer therapy	Ms. Divya Nagarajan, UK
7P	Combination of cetuximab with radioimmunotherapy significantly enhances therapeutic response in colorectal cancer	Vessela Vassileva, UK
8P	Safety of Imprime PGG, a novel innate immune modulator, in adults with Stage IV non-small cell lung cancer (NSCLC)	Michael Thomas, DE
9P	Low doses of cisplatin can help dendritic cell vaccine to reduce immunosuppression in tumor microenvironment	Oleksandr Gorbach, UA
10P	Influence of tumor necrosis factor- α -thymosin- α 1 on the humoral and cellular immunity of patients with locally advanced breast cancer	Liubov Vladimirova, RU
11P	Advancing of apoptosis by miR-122-5p in combination with trastuzumab in SKBR3 cell line	celaletdin camci, TR
12P	Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a cancer-associated ligand for inhibitory Siglecs	Heinz Läubli, CH
13P	Status of immune system of patients with endometrial cancer in dependence on the disease stage	Galina Zakora, RU
14P	Comparative analysis of tumor ploidy and local immunity in gut cancer	Oleg Kit, RU
15P	Significance of myofibroblast appearance at the invasive front in early-stage (T1/T2) oral squamous cell carcinoma (OSCC): A preliminary report	Petar Sutton, , HR
16TiP	A phase 3, randomised, double-blind, placebo-controlled, international study of MEDI4736 in patients with locally advanced, unresectable NSCLC (Stage III) who have not progressed following platinum-based, concurrent chemoradiation therapy (PACIFIC)	Scott Antonia, US
17TiP	A phase 2, non-comparative, open-label, international study of MEDI4736 in patients with locally advanced or metastatic PD-L1-positive NSCLC (Stage IIIB-IV) who have received ≥ 2 prior systemic treatment regimens (ATLANTIC)	Naiyer Rizvi, US
18TiP	Design of a phase 2 study of brentuximab vedotin (SGN-35) as salvage therapy for males with chemoresistant germ-cell tumors (GCT)	Patrizia Giannatempo, IT
19TiP	A phase 2 study of docetaxel in combination with indoximod for metastatic breast cancer	Eugene Kennedy, , US